Coherus BioSciences, Inc. (CHRS) News
Filter CHRS News Items
CHRS News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
CHRS News Highlights
- For CHRS, its 30 day story count is now at 9.
- Over the past 22 days, the trend for CHRS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about CHRS are DEC, PD and BODY.
Latest CHRS News From Around the Web
Below are the latest news stories about COHERUS BIOSCIENCES INC that investors may wish to consider to help them evaluate CHRS as an investment opportunity.
Why Coherus BioSciences Stock Jumped TodayCoherus finally received FDA approval for its Udenyca OnBody injector system. |
Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca OnbodyThe FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news. |
These Stocks Moved the Most Today: Tesla, Apple, Coinbase, MicroStrategy, Iovance, NetEase, and MoreA report says Tesla plans a revamped version of the Model Y from its Shanghai plant, while Apple shares are on pace to fall for a fifth-straight session. |
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv– Innovative design enables five-minute pegfilgrastim delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving pegfilgrastim – REDWOOD CITY, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer, today announced that the U.S. Food |
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall StreetThese two biotech stocks could be poised for a trend reversal. |
Coherus BioSciences Announces New Employment Inducement GrantsREDWOOD CITY, Calif., Dec. 22, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective December 20, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 192,000 shares of the common stock of the Company to five newly hired employees with a per share exercise price of $1.94, the closing trading price on the grant date. One Executive Vice President level executive was g |
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx– NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with chemotherapy; LOQTORZI monotherapy also recommended as the only preferred regimen in subsequent lines of therapy – -– LOQTORZI is the first and only FDA-approved treatment for recurrent or metastatic NPC in all lines of therapy– REDWOOD CITY, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, In |
Coherus BioSciences Announces CFO Transition PlansREDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced that McDavid Stilwell, Chief Financial Officer (CFO), has resigned from the company to pursue other opportunities. Mr. Stilwell’s last day of employment with Coherus will be December 31, 2023, with ongoing service provided beyond that date by mutual agreement. Coherus will appoint a new interim Principal Financial Officer in late December 2023 or early January 2024 while it |
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress– Casdozokitug has demonstrated anti-tumor activity alone and in combination with an anti-PD-1 antibody; two of nine squamous NSCLC patients had confirmed partial responses – – Data support continued evaluation of casdozokitug in combination with anti-PD-1 antibody treatments including ongoing Phase 2 cohort of casdozokitug with toripalimab in treatment refractory NSCLC – REDWOOD CITY, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced da |
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association– Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with LOQTORZI plus chemotherapy significantly prolongs survival in patients with recurrent or metastatic NPC irrespective of PDL-1 status– – Treatment resulted in a 37% reduction in the risk of death versus chemotherapy alone – -– LOQTORZI is the first and only FDA-approved treatment for recurrent or metastatic NPC in all lines of therapy and will be available to NPC patients in the U.S. in January 2024 – REDWOO |